Benzamide, N-[4-[[7-chloro-2,3,4,5-tetrahydro-5-[[3-(4-morpholinyl)-3-oxopropyl]amino]-1H-1-benzazepin-1-yl]carbonyl]-3-methylphenyl]-2-methyl- manufacturers
|
| | Benzamide, N-[4-[[7-chloro-2,3,4,5-tetrahydro-5-[[3-(4-morpholinyl)-3-oxopropyl]amino]-1H-1-benzazepin-1-yl]carbonyl]-3-methylphenyl]-2-methyl- Basic information |
| | Benzamide, N-[4-[[7-chloro-2,3,4,5-tetrahydro-5-[[3-(4-morpholinyl)-3-oxopropyl]amino]-1H-1-benzazepin-1-yl]carbonyl]-3-methylphenyl]-2-methyl- Chemical Properties |
| Boiling point | 741.2±60.0 °C(Predicted) | | density | 1.31±0.1 g/cm3(Predicted) | | pka | 13.00±0.70(Predicted) |
| | Benzamide, N-[4-[[7-chloro-2,3,4,5-tetrahydro-5-[[3-(4-morpholinyl)-3-oxopropyl]amino]-1H-1-benzazepin-1-yl]carbonyl]-3-methylphenyl]-2-methyl- Usage And Synthesis |
| Uses | Vasopressin V2 receptor antagonist 1 (Compound 4g) is a vasopressin V2 receptor (V2R) antagonist with a Ki of 3.8 nM. Vasopressin V2 receptor antagonist 1 can be used for autosomal dominant polycystic kidney disease (ADPKD) research[1]. | | References | [1] Haoran Zhang, et al. Long Residence Time at the Vasopressin V2 Receptor Translates into Superior Inhibitory Effects in Ex Vivo and In Vivo Models of Autosomal Dominant Polycystic Kidney Disease. J Med Chem. 2022 Apr 1. DOI:10.1021/acs.jmedchem.2c00011 |
| | Benzamide, N-[4-[[7-chloro-2,3,4,5-tetrahydro-5-[[3-(4-morpholinyl)-3-oxopropyl]amino]-1H-1-benzazepin-1-yl]carbonyl]-3-methylphenyl]-2-methyl- Preparation Products And Raw materials |
|